Additionally, pharmacological SIRT1 activators like SRT2104 have demonstrated side effects in clinical trials, including headaches, gastrointestinal disturbances, dizziness, and nasopharyngitis, often mild but highlighting tolerability concerns. This evidence concerns the gene SIRT1 and nasopharyngitis.